Genetic Variants of Rs628031 and Rs622342 and Glycemic Control in T2DM Patients from Northern Mexico

Overview

Journal Genes (Basel)

Publisher MDPI

Date 2025 Feb 26

PMID 40004467

Authors

Janette G Moreno-Gonzalez

Sandra A Reza-Lopez

Everardo Gonzalez-Rodriguez

Tania Samanta Siqueiros-Cendon

Alfonso Escareno Contreras

Quintin Rascon-Cruz

Irene Leal-Berumen

Affiliations

Soon will be listed here.

Abstract

Background: Type 2 diabetes mellitus (T2DM) and its associated complications are of public health concern. Metformin is the most common pharmacological T2DM treatment, distributed through organic cation transporters (s). The solute transporter family 22A1 () gene encodes , and its variants may play a role in glycemic control. This study analyzed seven gene variants and their potential association with glycemic control in patients from Northern Mexico with T2DM undergoing metformin monotherapy.

Methods: This cross-sectional study included 110 patients. We analyzed HbA1c values as a continuous variable and according to glycemic control categories (<7% vs. ≥7%). DNA from blood samples was genotyped using genotyping assays based on real-time PCR and PCR-RFLP.

Results: Patients with GG or AA rs628031 genotypes were 2.7 times more likely to have inadequate glycemic control than those with the GA genotype ( = 0.042). We analyzed the combination of rs628031 and rs622342 as diplotypes. The relation between HbA1c and these diplotypes was influenced by BMI and the metformin dose. Carriers of at least one minor allele of A-rs628031 and C-rs622342 had lower HbA1c values than individuals homozygous for the major allele in both genes.

Conclusions: The rs628031 and rs622342 variants are associated with lower HbA1c levels in T2DM patients. Larger studies are needed to confirm these associations.

References

Mofo Mato E, Guewo-Fokeng M, Essop M, Owira P . Genetic polymorphisms of organic cation transporter 1 (OCT1) and responses to metformin therapy in individuals with type 2 diabetes: A systematic review. Medicine (Baltimore). 2018; 97(27):e11349. PMC: 6076123. DOI: 10.1097/MD.0000000000011349. View

Zhou K, Donnelly L, Kimber C, Donnan P, Doney A, Leese G . Reduced-function SLC22A1 polymorphisms encoding organic cation transporter 1 and glycemic response to metformin: a GoDARTS study. Diabetes. 2009; 58(6):1434-9. PMC: 2682689. DOI: 10.2337/db08-0896. View

Zepeda-Carrillo E, Ramos-Lopez O, Martinez-Lopez E, Barron-Cabrera E, Bernal-Perez J, Velasco-Gonzalez L . Effect of Metformin on Glycemic Control Regarding Carriers of the (rs628031) Polymorphism and Its Interactions with Dietary Micronutrients in Type 2 Diabetes. Diabetes Metab Syndr Obes. 2022; 15:1771-1784. PMC: 9196279. DOI: 10.2147/DMSO.S354579. View

Zhang S, Zhu A, Kong F, Chen J, Lan B, He G . Structural insights into human organic cation transporter 1 transport and inhibition. Cell Discov. 2024; 10(1):30. PMC: 10940649. DOI: 10.1038/s41421-024-00664-1. View

ElSayed N, Aleppo G, Aroda V, Bannuru R, Brown F, Bruemmer D . 3. Prevention or Delay of Type 2 Diabetes and Associated Comorbidities: Standards of Care in Diabetes-2023. Diabetes Care. 2022; 46(Suppl 1):S41-S48. PMC: 9810464. DOI: 10.2337/dc23-S003. View

Monnerat G, Maior A, Tannure M, Back L, Santos C . Single-Nucleotide-Polymorphism-Panel Population-Genetics Approach Based on the 1000 Genomes Database and Elite Soccer Players. Int J Sports Physiol Perform. 2018; 14(6):711-717. DOI: 10.1123/ijspp.2018-0715. View

Ortega-Ayala A, Rodriguez-Rivera N, de Andres F, LLerena A, Perez-Silva E, Espinosa-Sanchez A . Pharmacogenetics of Metformin Transporters Suggests No Association with Therapeutic Inefficacy among Diabetes Type 2 Mexican Patients. Pharmaceuticals (Basel). 2022; 15(7). PMC: 9318506. DOI: 10.3390/ph15070774. View

Wang D, Jonker J, Kato Y, Kusuhara H, Schinkel A, Sugiyama Y . Involvement of organic cation transporter 1 in hepatic and intestinal distribution of metformin. J Pharmacol Exp Ther. 2002; 302(2):510-5. DOI: 10.1124/jpet.102.034140. View

Phani N, Vohra M, Kakar A, Adhikari P, Nagri S, Dsouza S . Implication of critical pharmacokinetic gene variants on therapeutic response to metformin in Type 2 diabetes. Pharmacogenomics. 2018; 19(11):905-911. DOI: 10.2217/pgs-2018-0041. View

10.

Al-Eitan L, Almomani B, Nassar A, Elsaqa B, Saadeh N . Metformin Pharmacogenetics: Effects of SLC22A1, SLC22A2, and SLC22A3 Polymorphisms on Glycemic Control and HbA1c Levels. J Pers Med. 2019; 9(1). PMC: 6462993. DOI: 10.3390/jpm9010017. View

11.

Barcelos E, Naslavsky M, Fernandes I, Scliar M, Yamamoto G, Wang J . Genetic variation in NOTCH1 is associated with overweight and obesity in Brazilian elderly. Sci Rep. 2024; 14(1):17096. PMC: 11269636. DOI: 10.1038/s41598-024-65771-1. View

12.

Resendiz-Abarca C, Flores-Alfaro E, Suarez-Sanchez F, Cruz M, Valladares-Salgado A, Alarcon-Romero L . Altered Glycemic Control Associated With Polymorphisms in the SLC22A1 (OCT1) Gene in a Mexican Population With Type 2 Diabetes Mellitus Treated With Metformin: A Cohort Study. J Clin Pharmacol. 2019; 59(10):1384-1390. DOI: 10.1002/jcph.1425. View

13.

Koepsell H, Lips K, Volk C . Polyspecific organic cation transporters: structure, function, physiological roles, and biopharmaceutical implications. Pharm Res. 2007; 24(7):1227-51. DOI: 10.1007/s11095-007-9254-z. View

14.

. Abridged for Primary Care Providers. Clin Diabetes. 2023; 41(1):4-31. PMC: 9845083. DOI: 10.2337/cd23-as01. View

15.

Tarasova L, Kalnina I, Geldnere K, Bumbure A, Ritenberga R, Nikitina-Zake L . Association of genetic variation in the organic cation transporters OCT1, OCT2 and multidrug and toxin extrusion 1 transporter protein genes with the gastrointestinal side effects and lower BMI in metformin-treated type 2 diabetes patients. Pharmacogenet Genomics. 2012; 22(9):659-66. DOI: 10.1097/FPC.0b013e3283561666. View

16.

Whirl-Carrillo M, Huddart R, Gong L, Sangkuhl K, Thorn C, Whaley R . An Evidence-Based Framework for Evaluating Pharmacogenomics Knowledge for Personalized Medicine. Clin Pharmacol Ther. 2021; 110(3):563-572. PMC: 8457105. DOI: 10.1002/cpt.2350. View

17.

Shu Y, Leabman M, Feng B, Mangravite L, Huang C, Stryke D . Evolutionary conservation predicts function of variants of the human organic cation transporter, OCT1. Proc Natl Acad Sci U S A. 2003; 100(10):5902-7. PMC: 156299. DOI: 10.1073/pnas.0730858100. View

18.

Kerb R, Brinkmann U, Chatskaia N, Gorbunov D, Gorboulev V, Mornhinweg E . Identification of genetic variations of the human organic cation transporter hOCT1 and their functional consequences. Pharmacogenetics. 2002; 12(8):591-5. DOI: 10.1097/00008571-200211000-00002. View

19.

Ebid A, Ehab M, Ismail A, Soror S, Mahmoud M . The influence of rs622342 and rs757110 genetic variants on the efficacy of metformin and glimepiride combination therapy in Egyptian patients with type 2 diabetes. J Drug Assess. 2019; 8(1):115-121. PMC: 6566583. DOI: 10.1080/21556660.2019.1619571. View

20.

Singh S, Usman K, Banerjee M . Pharmacogenetic studies update in type 2 diabetes mellitus. World J Diabetes. 2016; 7(15):302-15. PMC: 4980637. DOI: 10.4239/wjd.v7.i15.302. View